Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways
Authors:
- Vanshika GargVanshika Garg
- Raphael N. H. M. HofmannRaphael N. H. M. Hofmann
- Moazzam SaleemMoazzam Saleem
- Amin MirzaiebadiziAmin Mirzaiebadizi
- Ghazaleh Sadat HashemiGhazaleh Sadat Hashemi
- Tooba HameedTooba Hameed
- Bahareh JooyehBahareh Jooyeh
- Silke PudewellSilke Pudewell
- Mehrnaz MehrabipourMehrnaz Mehrabipour
- Niloufar MosaddeghzadehNiloufar Mosaddeghzadeh
- Roland P. PiekorzRoland P. Piekorz
- Mohammad Reza AhmadianMohammad Reza Ahmadian
Open Access
Abstract
The oncogene KRAS drives tumor growth by activating pathways such as MAPK and PI3K-AKT in a constitutive manner. Although direct KRAS inhibitors exist, they are often limited in clinical use due to therapeutic resistance and toxicity. Therefore, alternative combinatorial therapeutic strategies are urgently needed. This study examined the knockout of five KRAS-related proteins—galectin-3 (GAL3), phosphodiesterase delta (PDEδ), nucleophosmin (NPM1), IQ motif-containing GTPase-activating protein 1 (IQGAP1), and SHOC2—using CRISPR-Cas9 in adenocarcinoma cell lines harboring the KRAS(G12V) oncogenic mutation, as well as in the noncancerous HEK-293 cell line. These proteins act as critical modulators that regulate KRAS activity, cellular localization, and that of its downstream signaling components. We analyzed the downstream activation of ERK and AKT kinases and evaluated subsequent cancer cell proliferation. Knockout of GAL3 and PDEδ was highly effective, significantly reducing MAPK and PI3K-AKT pathway activity and substantially impairing cell proliferation. SHOC2 knockout selectively and potently disrupted MAPK activation, while NPM1 knockout resulted in the complex, reciprocal modulation of the two major pathways. Notably, knocking out IQGAP1 enhanced PI3K–AKT and mTORC2–AKT signaling without affecting the MAPK pathway. These distinct modulatory roles highlight the non-redundant functions of the accessory proteins. In conclusion, our findings establish GAL3 and PDEδ, two KRAS-associated proteins, as promising combinatorial drug targets. Targeting these modulators provides an effective alternative strategy to overcome resistance mechanisms and enhance the clinical utility of existing KRAS inhibitors.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (AH 92/8-3)
- European Network on Noonan Syndrome and Related Disorders (01GM1602B)
This publication has 130 references indexed in Scilit:
- Whole‐genome CRISPR‐Cas9 knockout screens identify SHOC2 as a genetic dependency in NRAS ‐mutant melanomaCancer Communications, 2025
- AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancerCellular and Molecular Life Sciences, 2022
- Clinical and functional characterization of a novel RASopathy‐causingSHOC2mutation associated with prenatal‐onset hypertrophic cardiomyopathyHuman Mutation, 2019
- A PDE6δ‐KRas Inhibitor Chemotype with up to Seven H‐Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2Angewandte Chemie International Edition, 2017
- Further evidence that variants in PPP1CB cause a rasopathy similar to Noonan syndrome with loose anagen hairAmerican Journal of Medical Genetics Part A, 2016
- A NovelSHOC2Variant in RasopathyHuman Mutation, 2014
- Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemiaAnnals of Hematology, 2014
- Overexpression of IQGAP1 in advanced colorectal cancer correlates with poor prognosis—critical role in tumor invasionInternational Journal of Cancer, 2010
- Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissueProteomics, 2004
- Binding of Myosin Essential Light Chain to the Cytoskeleton-Associated Protein IQGAP1Biochemical and Biophysical Research Communications, 1998